Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer

Sawicki, L; Grueneisen, Johannes; Schaarschmidt, Benedikt Michael; Buchbender, Christian; Nagarajah, James; Umutlu, Lale; Antoch, Gerald; Kinner, Sonja

doi:10.1016/j.ejrad.2015.12.010

Cited by 85 publications

(72 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though for the primary tumor a histopathological correlation was available, due to ethical reasons a histopathological sampling of each detected lesion was not applicable. To overcome this limitation, a well-established modified reference standard was applied [39,40] comprising all available data based on clinical follow-up, imaging and histopathology.…”

Section: Discussionmentioning

confidence: 99%

18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectivesTo evaluate the added value of the application of the liver-specific contrast phase of Gadobenate dimeglumine (Gd-BOPTA) for detection and characterization of liver lesions in 18F-FDG PET/MRI.Methods41 patients with histologically confirmed solid tumors and known / suspected liver metastases or not classifiable lesions in 18F-FDG PET/CT were included in this study. All patients underwent a subsequent Gd-BOPTA enhanced 18F-FDG PET/MRI examination. MRI without liver-specific contrast phase (MRI1), MRI with liver-specific contrast phase (MRI2), 18F-FDG PET/MRI without liver-specific contrast phase (PET/MRI1) and with liver-specific contrast phase (PET/MRI2) were separately evaluated for suspect lesions regarding lesion dignity, characterization, conspicuity and confidence.ResultsPET/MRI datasets enabled correct identification of 18/18 patients with malignant lesions; MRI datasets correctly identified 17/18 patients. On a lesion-based analysis PET/MRI2 provided highest accuracy for differentiation of lesions into malignant and benign lesions of 98% and 100%. Respective values were 95% and 100% for PET/MRI1, 93% and 96% for MRI2 and 91% and 93% for MRI1. Statistically significant higher diagnostic confidence was found for PET/MRI2 and MRI2 datasets compared to PET/MRI1 and MRI1, respectively (p < 0.001).ConclusionThe application of the liver-specific contrast phase in 18F-FDG PET/MRI further increases the diagnostic accuracy and diagnostic confidence for correct assessment of benign and malignant liver lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a further refinement of the combined approach, PET/MRI was recently introduced with excellent soft tissue resolution (Partovi et al, 2014). The superiority of PET/MRI over PET/CT in cancer diagnosis were confirmed in multiple recent studies including oncolytic bone lesions (Beiderwellen et al, 2014), liver metastasis (Beiderwellen, Geraldo, et al, 2015), detecting malignant/benign lesions in recurrent breast cancer patients (Sawicki et al, 2016), recurrent female malignancies such as ovarian cancer (Beiderwellen, Grueneisen, et al, 2015), thyroid cancer (Nagarajah et al, 2011), pancreatic (Nagamachi et al, 2013), and head and neck (Queiroz & Huellner, 2015) cancers. In pancreatic and head and neck cancer studies, although PET/MRI is sensitive over PET/CT, the differences were not statistically significant.…”

Section: Approaches Used To Detect Metastatic Lesions (On a Clinicmentioning

confidence: 85%

Detecting Tumor Metastases

Menezes

Das

Minn

et al. 2016

Advances in Cancer Research

View full text Add to dashboard Cite

Metastasis is the complex process by which primary tumor cells migrate and establish secondary tumors in an adjacent or distant location in the body. Early detection of metastatic disease and effective therapeutic options for targeting these detected metastases remain impediments to effectively treating patients with advanced cancers. If metastatic lesions are identified early, patients might maximally benefit from effective early therapeutic interventions. Further, monitoring patients whose primary tumors are effectively treated for potential metastatic disease onset is also highly valuable. Finally, patients with metastatic disease can be monitored for efficacy of specific therapeutic interventions through effective metastatic detection techniques. Thus, being able to detect and visualize metastatic lesions is key and provides potential to greatly improve overall patient outcomes. In order to achieve these objectives, researchers have endeavored to mechanistically define the steps involved in the metastatic process as well as ways to effectively detect metastatic progression. We presently overview various preclinical and clinical in vitro and in vivo assays developed to more efficiently detect tumor metastases, which provides the foundation for developing more effective therapies for this invariably fatal component of the cancerous process.

show abstract

“…Since the last meeting, there have been further published studies of the diagnostic potential of PET/MRI in cancers of the cervix [46], endometrium [47], colorectal [48], breast [49], head and neck [50], and thyroid and metastatic prostate disease [51] in comparison to PET/CT and for response prediction in gastric cancer [52]. However, the number of patients studied remains relatively small.…”

Section: Dialogue Board 3: Oncologymentioning

confidence: 99%

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany

et al. 2016

View full text Add to dashboard Cite

This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.

show abstract

Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer

Cited by 85 publications

References 26 publications

18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine

18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine

Detecting Tumor Metastases

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany

Contact Info

Product

Resources

About